Close Menu

Breaking News

The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.

The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.

The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. 

Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.

About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.

The firms have developed a cannabis sequencing panel, called myBaits MGC Cannabis Panel, which they will be offering  for sequencing service work.

The funding will support the use of a new in situ RNA sequencing technology, STARmap, to build functional maps of the developing brain and brain tumors.

The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.

Columbia and Qiagen filed a suit against Illumina in federal court today, alleging infringement of two patents that were issued today.

The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.

The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.

The funding is being provided by the Flemish government's Agency for Innovation and Entrepreneurship to support the three-year development project.

The victory for the sequencing giant is just the latest in a string of favorable decisions before the US Patent Trial and Appeals Board.

A Mendelian randomization analysis found visceral fat to be linked to cardiometabolic disease risk, especially type 2 diabetes risk in women.

The synthetic biology and DNA data storage firm will use the funds to launch its BioXp 3200 automated gene synthesis and cloning platform.

CFSRE recently validated Verogen's NGS-based forensics platform and will develop implementation and training materials for law enforcement.

MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.

Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.

Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.

The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.

Last week, GenomeWeb's readers were most interested in 10x Genomics' countersuit against Becton Dickinson for patent infringement.

The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.

The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.

Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.